other material
confidence high
sentiment positive
materiality 0.85
Axsome solriamfetol Phase 3 ADHD trial meets primary endpoint (p=0.039)
Axsome Therapeutics, Inc.
- AISRS total score reduced 17.7 pts vs 14.3 for placebo at Week 6 (p=0.039) with 150 mg dose.
- Key secondary endpoint CGI-S severity score also significant (p=0.017) for 150 mg solriamfetol.
- 53.5% of 150 mg patients achieved clinical response (≥30% AISRS reduction) vs 41.3% placebo (p=0.024).
- Onset of improvement observed as early as Week 1 (p=0.036) vs placebo.
- Company plans to initiate pediatric ADHD trial in 2025; safety profile consistent with prior studies.